ELV Stock - Elevance Health Inc.

The preliminary 2027 Medicare Advantage (MA) Advance Notice, released by the Centers for Medicare & Medicaid Services (CMS) in late January 2026, presents a challenging reimbursement environment for managed care organizations. For Elevance Health (ELV), the announcement necessitates a continued pivot toward margin preservation over membership expansion, potentially impacting its competitive benefit offerings for the 2027 plan year.

2027 CMS Rate Announcement: Key Metrics

The 2027 Advance Notice is characterized by a "flat" base rate environment that significantly trails historical medical cost trends.

• Net Payment Update: CMS projected a net average year-over-year payment increase of only 0.09%. This figure is substantially lower than the 5.06% increase finalized for 2026.
• Expected Average Change: When accounting for the MA risk score trend (coding practices), CMS projects an effective payment increase of 2.54%.
• Market Discrepancy: The proposed update fell well short of institutional expectations, which had forecasted a rate hike in the 4% to 6% range to account for elevated utilization and medical inflation.

Risk Adjustment and Revenue Headwinds

A critical component of the 2027 proposal is the structural shift in risk adjustment methodology, specifically targeting "documentation arbitrage."

• Unlinked Chart Reviews: CMS proposes to exclude diagnoses derived from "unlinked" chart reviews—records not tied to a specific beneficiary encounter—from risk-score calculations. This change is estimated to save Medicare over $7B in 2027.
• Impact on Elevance: While UnitedHealth Group has the highest absolute exposure, Elevance Health maintains "comparable levels" of enrollees whose risk scores are supported by these audits. The exclusion of these diagnoses represents a direct headwind to revenue yields.
• Model Recalibration: The continued phase-in of the V28 risk adjustment model, recalibrated with 2023-2024 data, further pressures risk scores by approximately -3.32% (combined with normalization).

Impact on Elevance Health’s Margin Targets

Elevance Health entered 2026 in a "repositioning" phase, having already signaled a retreat from aggressive growth to restore profitability in its Health Benefits segment.

• 2027 EPS Target: Management has reaffirmed a long-term goal of at least 12% adjusted EPS growth for 2027. Achieving this against a 0.09% base rate update requires significant internal "pricing discipline."
• Margin Recalibration: Following a 150 basis point increase in the 2025 benefit expense ratio (to 90.0%), ELV is aggressively recalibrating segment margins. The 2027 rates likely force a continuation of the strategy seen in 2026, where MA membership is expected to decline in the "high 10s" percentage range due to plan exits.
• Star Ratings Support: A partial mitigant is ELV’s improved quality performance; approximately 55% of its members are in contracts rated 4-Star or higher for the 2027 payment year, which helps secure Quality Bonus Payments (QBPs).

Competitive Benefit Positioning

The mismatch between the 2.54% expected revenue increase and medical trends (often exceeding 6-7%) creates a "funding gap" that must be closed through benefit adjustments.

• Supplemental Benefit Cuts: To maintain its 12% growth algorithm, Elevance may be forced to reduce "non-core" supplemental benefits such as dental, vision, hearing, and transportation allowances.
• Premium Adjustments: In markets where margins remain below targets, ELV is likely to prioritize premium increases or higher out-of-pocket maximums, even at the risk of further membership attrition.
• Market Rationalization: The company is expected to continue its "disciplined" approach, potentially exiting counties or service areas where the 2027 benchmarks do not support sustainable 3-5% operating margins.

Risks and Uncertainties

• Final Rate Announcement: The final rates, due in April 2026, may be adjusted based on industry lobbying and updated Medicare fee-for-service data.
• Utilization Volatility: If outpatient and orthopedic utilization remains elevated through 2026, the 2.54% revenue update will be insufficient to cover cost growth, leading to further margin compression.
• Regulatory Shifts: The proposed exclusion of audio-only telehealth diagnoses from risk scoring adds another layer of operational risk for plans serving rural or less-mobile populations.

Elevance Health’s (ELV) Q4 2025 results and subsequent 2026 guidance, released on January 28, 2026, signal a strategic "reset" year. While the company reported a beat on Q4 adjusted EPS, the 93.5% Medical Loss Ratio (MLR) for the quarter underscores persistent utilization pressures. Management’s 2026 outlook reflects a cautious stance, pricing in elevated outpatient trends rather than assuming a rapid return to historical norms.

Q4 2025 Performance and MLR Dynamics

Elevance reported Q4 2025 adjusted EPS of $3.33, surpassing the consensus estimate of $3.10. However, this performance was heavily influenced by tax favorability and non-recurring items. The core focus remained on the consolidated benefit expense ratio (MLR), which reached 93.5% in Q4, an increase of 110 basis points year-over-year.

• Full-Year 2025 MLR: Finished at 90.0%, up 150 basis points from 2024.
• Primary Drivers: The spike was attributed to higher medical cost trends in Affordable Care Act (ACA) plans and heightened Medicare Part D seasonality following Inflation Reduction Act (IRA) changes.
• Utilization Consistency: Management noted that while costs remained high, the development of these trends in Q4 was "consistent with expectations," suggesting that the volatility seen earlier in 2025 has begun to level off into a predictable, albeit elevated, baseline.

Evidence of Utilization Stabilization in Early 2026

Data from the Q4 earnings call and early 2026 projections provide a nuanced view of outpatient utilization:

1. Predictable Trend Lines: Management stated that cost trends across major lines of business are now developing in line with their internal models. This "predictability" is the first stage of stabilization, allowing for more accurate pricing in the 2026 contract year.
2. Medicaid "Trough" Assessment: Elevance identified 2026 as the "trough" for Medicaid margins, projecting an operating margin of approximately -1.75%. This assumes that while utilization remains high, the mismatch between member acuity and state reimbursement rates is being addressed through active rate negotiations.
3. Aggressive ACA Repositioning: To counter higher member morbidity and outpatient utilization in the Individual market, Elevance implemented a composite rate increase of approximately 20% for 2026. This suggests the company is no longer waiting for utilization to drop but is instead "pricing to trend."
4. Medicare Advantage (MA) Discipline: The company is intentionally reducing its MA membership by "high teens" percentages in 2026. By exiting less profitable counties and refining benefits, Elevance aims to stabilize its MA MLR and improve segment margins to at least 2%.

Implications for FY 2026 Adjusted EPS Guidance

Elevance issued a 2026 adjusted EPS guidance of "at least $25.50," a significant reduction from the $30.29 reported in 2025. This guidance reflects several critical assumptions:

• Normalization of Earnings: The 2025 results included $3.75 per share in non-recurring favorable items (primarily tax-related). Excluding these, the 2026 guide represents a conservative "floor" as the company navigates the Medicaid margin trough.
• MLR Target: The 2026 benefit expense ratio is projected at 90.2% ± 50 basis points. This target acknowledges that outpatient utilization will remain at current levels, with margin recovery driven by pricing power and Carelon’s growth rather than a decrease in medical demand.
• Revenue Headwinds: Operating revenue is expected to decline in the low single-digit range as the company prioritizes margin over membership volume, particularly in Medicaid and Medicare Advantage.

Risks and Forward Outlook

While Elevance is taking "decisive action" to stabilize margins, several uncertainties remain:

• Rate Adequacy: The 2027 CMS Advance Notice suggests a flat net rate increase of 0.09%, which may continue to lag behind medical inflation and outpatient surgery trends.
• Medicaid Redeterminations: Ongoing attrition in Medicaid (-750,000 members projected for 2026) continues to shift the risk pool toward higher-acuity members.
• Recovery Path: Despite the 2026 reset, management reaffirmed its long-term growth algorithm, targeting a return to at least 12% adjusted EPS growth in 2027.

The legislative environment surrounding Pharmacy Benefit Managers (PBMs) has reached a critical inflection point with the enactment of the Consolidated Appropriations Act of 2026 (signed February 3, 2026). For Elevance Health (ELV), this regulatory shift specifically targets the Carelon segment—the company’s primary engine for margin diversification. The following analysis quantifies the valuation risks and operational margin trajectory for the next 12 to 18 months.

Carelon Segment Profile and Revenue Mix

Carelon, which includes CarelonRx (PBM) and Carelon Services, has been the primary driver of Elevance’s growth as the Health Benefits segment (insurance) faced Medicaid redetermination headwinds.

• 2025 Performance: Carelon generated $71.7B in operating revenue, a 33% year-over-year increase.
• Margin Compression: Despite revenue growth, Carelon’s adjusted operating margin contracted to 4.8% in 2025, down from 5.8% in 2024. This reflects early-stage shifts in contract mix and increased investments in specialty pharmacy.
• Operating Gain: The segment contributed $3.4B to the consolidated adjusted operating gain in 2025, representing approximately 45% of the enterprise total.

Legislative Transmission Mechanisms

The 2026 federal legislation and concurrent state-level mandates (with over 880 PBM-related bills active across U.S. states) introduce three primary transmission mechanisms for financial risk:

1. Medicare Part D "Delinking" (Federal): The new law mandates that by 2028, PBM compensation in Medicare Part D must be restricted to flat, "bona fide" service fees. While the hard deadline is 2028, the 12-18 month window will see ELV restructuring its 2027 and 2028 bids. This removes the ability to monetize rebates or price-linked administrative fees, which historically carried higher margins than flat-fee models.
2. Spread Pricing Bans (State-Level): At least 23 states have introduced or passed legislation prohibiting "spread pricing" (the difference between what a PBM charges a plan and pays a pharmacy). For CarelonRx, which utilizes spread pricing in certain Medicaid and commercial contracts, this forces a transition to "pass-through" models, typically resulting in a 15-25 bps margin headwind per affected contract.
3. Transparency & Audit Rights: Enhanced reporting requirements allow plan sponsors to verify net drug spending. This increased "transparency" reduces the PBM's information asymmetry, likely leading to more aggressive contract renegotiations by commercial clients in the 2026-2027 cycle.

Quantified Valuation Risk & Margin Trajectory

The market has begun pricing in a "trough year" for Elevance in 2026, driven by the convergence of PBM regulation and Medicare Advantage (MA) payment pressures.

• Consolidated Margin Outlook: Management has guided to a 2026 adjusted operating gain of at least $6.8B, a significant decline from the $7.5B reported in 2025. The consolidated adjusted operating margin is expected to remain pressured near 3.5% - 3.8% through mid-2027.
• Carelon Margin Sensitivity: If fee-structure mandates accelerate the shift away from spread pricing and retained rebates, Carelon’s operating margin could settle in the 4.2% - 4.5% range. A 50 bps permanent margin contraction in Carelon equates to approximately $350M - $400M in lost annual operating income.
• EPS Impact: Elevance’s 2026 adjusted EPS guidance of "at least $25.50" (down from $30.29 in 2025) reflects these regulatory and operational realities. While $3.75 of the decline is attributed to non-recurring tax items, the remaining gap is largely due to margin compression in government-backed plans and PBM repositioning.

Strategic Risks & Uncertainties

• Contractual Repricing: The primary risk over the next 18 months is the "repricing cycle." As ELV moves to flat-fee structures to comply with federal transparency standards, it must increase administrative fees to offset lost rebate/spread revenue. Failure to achieve "fee parity" could lead to further margin erosion.
• Vertical Integration Scrutiny: Proposed legislation (e.g., House Bill 7148) includes provisions that could eventually challenge the "Any Willing Pharmacy" barriers, potentially diluting the profitability of Carelon’s captive specialty and mail-order pharmacy assets.
• Valuation Multiple: ELV has historically traded at a forward P/E of 12x - 14x. Current regulatory uncertainty and the "trough year" outlook have compressed this to approximately 10x - 11x on 2026 estimates, representing a 15% - 20% valuation discount relative to historical averages.